Last reviewed · How we verify
NCT05474573: CONFLUENSE
Concurrent Fluorescence and Sonographically Guided Eradication of Contrast-enhancing Gliomas and Metastases
NA trial testing Combined ultrasound and fluorescence-guided brain tumor resection in Glioma, Malignant in 52 participants. Currently enrolling.
31 August 2027
Quick facts
| Lead sponsor | Sklifosovsky Institute of Emergency Care |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 52 |
| Start date | 1 September 2022 |
| Primary completion | 31 August 2027 |
| Estimated completion | 31 August 2027 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- Combined ultrasound and fluorescence-guided brain tumor resection
- Fluorescence-guided brain tumor resection
Conditions studied
- Glioma, Malignant — all drugs for Glioma, Malignant →
- Metastases to Brain — all drugs for Metastases to Brain →
Sponsor
Sklifosovsky Institute of Emergency Care
Who can join
Adults 18 to 79, any sex, with Glioma, Malignant or Metastases to Brain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Objective of the study is to determine whether combined use of intraoperative fluorescence with 5-aminolevulinic acid (5-ALA) and sonography can achieve higher rate of gross total resection of contrast-enhancing gliomas and brain metastases compared to intraoperative fluorescence with 5-ALA alone.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05474573
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glioma, Malignant
Currently open trials in the same condition.
- NCT06917885 — CUE-102 in Recurrent Glioblastoma · Phase 1 · recruiting
- NCT06942104 — Imaging of Solid Tumors Using 18F-TRX · Phase 1 · recruiting
- NCT06169280 — Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma · Phase 1 · recruiting
- NCT06636162 — Window of Opportunity Study of DSP-0390 in Gliomas · EARLY_PHASE1 · recruiting
- NCT06810544 — Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss · Phase 1, PHASE2 · recruiting
Other Sklifosovsky Institute of Emergency Care trials
Trials by the same sponsor.
- NCT06059820 — Effectiveness of Conservative Treatment in Patients With Thoracic and Lumbar Fractures Without Neurological Deficit · completed
- NCT05693181 — Cord Blood Cells in Patients With Acute SCI · Phase 1, PHASE2 · unknown
- NCT05470374 — Intraoperative Sonographically Guided Resection of Non-enhancing Gliomas · NA · suspended
- NCT05477680 — Intraoperative Brain Shift Calculation Study · NA · recruiting
- NCT05485038 — General Anesthesia Versus Awake Surgery in Resection of Gliomas and Metastases of Motor Areas · NA · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05474573 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sklifosovsky Institute of Emergency Care
- Last refreshed: 16 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05474573.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing